Risk score = LncRNAs associated with doxorubicin metabolism can be used as molecular markers for immune microenvironment and immunotherapy in non-small cell lung cancer
Qianyi Lin,
Ming Zhang,
Ying Kong,
Ziyuan Huang,
Zhuoheng Zou,
Zhuolong Xiong,
Xiaolin Xie,
Zitong Cao,
Wanyi Situ,
Jiaxin Dong,
Shufang Li,
Xiao Zhu,
Yongmei Huang
Affiliations
Qianyi Lin
The Marine Biomedical Research Institute, Guangdong Medical University, Zhanjiang 524023, China
Ming Zhang
Department of Physical Medicine and Rehabilitation, Zibo Central Hospital, Zibo 255000, China
Ying Kong
Department of Clinical Laboratory, Hubei Province No.3 People's Hospital, Wuhan 430030, China
Ziyuan Huang
The Marine Biomedical Research Institute, Guangdong Medical University, Zhanjiang 524023, China
Zhuoheng Zou
The Marine Biomedical Research Institute, Guangdong Medical University, Zhanjiang 524023, China
Zhuolong Xiong
The Marine Biomedical Research Institute, Guangdong Medical University, Zhanjiang 524023, China
Xiaolin Xie
The Marine Biomedical Research Institute, Guangdong Medical University, Zhanjiang 524023, China
Zitong Cao
The Marine Biomedical Research Institute, Guangdong Medical University, Zhanjiang 524023, China
Wanyi Situ
The Marine Biomedical Research Institute, Guangdong Medical University, Zhanjiang 524023, China
Jiaxin Dong
The Marine Biomedical Research Institute, Guangdong Medical University, Zhanjiang 524023, China
Shufang Li
The Marine Biomedical Research Institute, Guangdong Medical University, Zhanjiang 524023, China
Xiao Zhu
The Marine Biomedical Research Institute, Guangdong Medical University, Zhanjiang 524023, China; Corresponding author.
Yongmei Huang
The Marine Biomedical Research Institute, Guangdong Medical University, Zhanjiang 524023, China; Corresponding author.
Doxorubicin is the most effective anthracycline chemotherapy drug in the treatment of cancer, and it is an effective single agent in the treatment of non-small cell lung cancer (NSCLC). There is a lack of studies on the differentially expressed doxorubicin metabolism-related lncRNAs in NSCLC. In this study, we extracted related genes from the TCGA database and matched them with lncRNAs. Doxorubicin metabolism-related lncRNA-based gene signatures (DMLncSig) were gradually screened from univariate regression, LASSO regression, and multivariate regression analysis, and the risk score model was constructed. These DMLncSig were subjected to a GO/KEGG analysis. We then used the risk model to construct the TME model and analyze drug sensitivity. The IMvigor 210 immunotherapy model was cited for validation. Eventually, we performed tumor stemness index differences, survival, and clinical correlation analyses.
